Welcome to our dedicated page for EDAP TMS S.A. news (Ticker: $EDAP), a resource for investors and traders seeking the latest updates and insights on EDAP TMS S.A. stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect EDAP TMS S.A.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of EDAP TMS S.A.'s position in the market.
EDAP reported robust growth in Q1 2024 with a significant 92% increase in U.S. Focal One® HIFU procedures year-over-year. HIFU revenue rose 10.2% to EUR 5.8 million ($6.3 million), contributing to a total revenue of EUR 14.9 million ($16.1 million), up 0.8% from Q1 2023. Gross profit increased to EUR 6.4 million ($6.9 million), driven by higher treatment revenues. Operating expenses dropped to EUR 11.2 million ($12.1 million) due to a non-recurring compensation expense in Q1 2023. Despite an operating loss of EUR 4.8 million ($5.2 million), net loss improved to EUR 4.5 million ($4.9 million) from EUR 7.5 million ($8.1 million) in Q1 2023. Additionally, EDAP's Phase 3 study on endometriosis is expected to yield results in the latter half of 2024.
EDAP TMS SA announced positive final results from the HIFI Study comparing Focal One® HIFU versus radical prostatectomy at the 119th AUA Annual Meeting. The study showed a higher salvage treatment free survival rate in the HIFU arm, better urinary continence and erectile function outcomes, and demonstrated the effectiveness and safety of robotic HIFU in managing localized prostate cancer. The study enrolled a total of 3,328 patients across 46 centers, highlighting the growing relevance of robotic HIFU in prostate cancer management.
EDAP TMS SA, a global leader in robotic energy-based therapies, will announce its first quarter 2024 financial results on May 16, 2024. The company will host a conference call and webcast with key executives to discuss the results. Investors can join the call to learn more about the financial performance and strategic direction of EDAP.